Therapeutic Asset Ratings

686 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Wellbutrin Breast Cancer	University of Illinois at Chicago	P4	B (60)
Abiraterone Acetate Breast Cancer	M.D. Anderson Cancer Center	P3	B (60)
Acetylsalicylic Acid Breast Cancer	The Christie NHS Foundation Trust	P3	B (60)
Calcium folinate pentahydrate Breast Cancer	Pfizer	P3	B (60)
CARMUSTINE Breast Cancer	General Oncology, Inc.	P3	B (60)
Dfn-15 Breast Cancer	Cairo University	P3	B (60)
ESTROGENS, CONJUGATED Breast Cancer	University of Kansas Medical Center	P3	B (60)
Evomela Breast Cancer	Delcath Systems Inc.	P3	B (60)
Famitinib Breast Cancer	Fudan University	P3	B (60)
Gdc-0068 Breast Cancer	German Cancer Research Center	P3	B (60)
Inavolisib Breast Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	B (60)
MEGESTROL ACETATE IMPURITY B Breast Cancer	Sun Yat-sen University	P3	B (60)
Neratinib Breast Cancer	Xijing Hospital	P3	B (60)
PREDNISONE TABLETS Breast Cancer	M.D. Anderson Cancer Center	P3	B (60)
Sargramostim Breast Cancer	University of Washington	P3	B (60)
TESTOSTERONE UNDECYLATE Breast Cancer	Aminex Therapeutics, Inc.	P3	B (60)
MELATONIN Breast Cancer	Mansoura University	P2/3	B (60)
Tranexamic Acid Breast Cancer	University of Virginia	P4	B (59)
Fludarabine Breast Cancer	Vall d'Hebron Institute of Oncology	P3	B (59)
Nivolumab Breast Cancer	Jennifer Zhang	P3	B (59)
Sorafenib Breast Cancer	Fudan University	P3	B (59)
Veliparib Breast Cancer	The University of Texas Health Science Center at San Antonio	P3	B (59)
Panobinostat Breast Cancer	Dana-Farber Cancer Institute	P2	B (59)
Loperamide Breast Cancer	Maryam Lustberg	P2/3	B (59)
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)- Breast Cancer	Fudan University	P4	B (58)

Showing 101 to 125 of 686 assets

PreviousPage 5 of 28Next